Medical School
- MD, Vanderbilt University School of Medicine (2007)
Undergraduate School
- BS, University of North Carolina–Chapel Hill (NC) (2003)
Residency
- Vanderbilt University Program, Internal Medicine (2010)
Fellowships
- University of Colorado (University Hospital) Program, Pulmonary Disease and Critical Care Medicine (2014)
Languages
EnglishDepartment
Medicine-Pulmonary Sciences & Critical CareProfessional Titles
- Associate Professor
Research Interests
My research focuses on understanding the molecular mechanisms that contribute to the formation of scar tissue in the lungs (pulmonary fibrosis). I have particular interests in fibrosis that develops following an infection (such as COVID or influenza) or ARDS, and understanding how these processes are both different and similar to more chronic forms of pulmonary fibrosis, such as Idiopathic Pulmonary Fibrosis (IPF). In my lab, we use cell culture, animal models of lung injury and fibrosis, and human samples that help bridge the gap between the bench and the bedside.Publications
- Auld SC, Sheshadri A, Alexander-Brett J, Aschner Y, Barczak AK, Basil MC, Cohen KA, Dela Cruz C, McGroder C, Restrepo MI, Ridge KM, Schnapp LM, Traber K, Wunderink RG, Zhang D, Ziady A, Attia EF, Carter J, Chalmers JD, Crothers K, Feldman C, Jones BE, Kaminski N, Keane J, Lewinsohn D, Metersky M, Mizgerd JP, Morris A, Ramirez J, Samarasinghe AE, Staitieh BS, Stek C, Sun J, Evans SE. Postinfectious Pulmonary Complications: Establishing Research Priorities to Advance the Field: An Official American Thoracic Society Workshop Report. Ann Am Thorac Soc. 2024 Sep;21(9):1219-1237. PubMed PMID: 39051991
- Hynds RE, Magin CM, Ikonomou L, Aschner Y, Beers MF, Burgess JK, Heise RL, Hume PS, Krasnodembskaya AD, Mei SHJ, Misharin AV, Park JA, Reynolds SD, Tschumperlin DJ, Tanneberger AE, Vaidyanathan S, Waters CM, Zettler PJ, Weiss DJ, Ryan AL. Stem cells, cell therapies, and bioengineering in lung biology and diseases 2023. Am J Physiol Lung Cell Mol Physiol. 2024 Sep 1;327(3):L327-L340. PubMed PMID: 38772903
- Sendo S, Kiosses WB, Yang S, Wu DJ, Lee DWK, Liu L, Aschner Y, Vela AJ, Downey GP, Santelli E, Bottini N. Clustering of phosphatase RPTPa promotes Src signaling and the arthritogenic action of synovial fibroblasts. Sci Signal. 2023 Jul 4;16(792):eabn8668. PubMed PMID: 37402225
- Ahangari F, Becker C, Foster DG, Chioccioli M, Nelson M, Beke K, Wang X, Justet A, Adams T, Readhead B, Meador C, Correll K, Lili LN, Roybal HM, Rose KA, Ding S, Barnthaler T, Briones N, DeIuliis G, Schupp JC, Li Q, Omote N, Aschner Y, Sharma L, Kopf KW, Magnusson B, Hicks R, Backmark A, Dela Cruz CS, Rosas I, Cousens LP, Dudley JT, Kaminski N, Downey GP. Saracatinib, a Selective Src Kinase Inhibitor, Blocks Fibrotic Responses in Preclinical Models of Pulmonary Fibrosis. Am J Respir Crit Care Med. 2022 Dec 15;206(12):1463-1479. PubMed PMID: 35998281
- Urban JA, Zirille F, Kiser TH, Aschner Y. Why So Salty? Transient Diabetes Insipidus After Discontinuation of Vasopressin. Ann Intern Med Clin Cases. 2022;1. PubMed PMID: 35782522
- Aschner Y, Correll KA, Beke KM, Foster DG, Roybal HM, Nelson MR, Meador CL, Strand M, Anderson KC, Moore CM, Reynolds PR, Kopf KW, Burnham EL, Downey GP. PTPa promotes fibroproliferative responses after acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2022 Jul 1;323(1):L69-L83. PubMed PMID: 35670474
- Aschner Y, Downey GP. Proteinases in the pathogenesis of lymphangioleiomyomatosis lung disease: nibbling or chewing up the lung?. Eur Respir J. 2022 Apr;59(4). PubMed PMID: 35422429
- Aschner Y, Nelson M, Brenner M, Roybal H, Beke K, Meador C, Foster D, Correll KA, Reynolds PR, Anderson K, Redente EF, Matsuda J, Riches DWH, Groshong SD, Pozzi A, Sap J, Wang Q, Rajshankar D, McCulloch CAG, Zemans RL, Downey GP. Protein tyrosine phosphatase-a amplifies transforming growth factor-ß-dependent profibrotic signaling in lung fibroblasts. Am J Physiol Lung Cell Mol Physiol. 2020 Aug 1;319(2):L294-L311. doi: 10.1152/ajplung.00235.2019. Epub 2020 Jun 3. PMID: 32491951; PMCID: PMC7473933.
- Aschner Y, Davidson JA. Early Plasma Matrix Metalloproteinase Profiles Offer New Insight into the Biology and Prognosis of Pediatric Acute Respiratory Distress Syndrome. Am J Respir Crit Care Med. 2018 Aug 30. [Epub ahead of print] PubMed PMID: 30160977
- Aschner Y, Downey GP. The Importance of Tyrosine Phosphorylation Control of Cellular Signaling Pathways in Respiratory Disease: pY and pY Not. Am J Respir Cell Mol Biol. 2018 Nov;59(5):535-547. PubMed PMID: 29812954
- Downey GP, Aschner Y. Taking It Off: New Insights into the Role of Tyrosine Phosphorylation-dependent Pathways in the Pathogenesis of Pulmonary Fibrosis. Am J Respir Crit Care Med. 2017 Feb 15;195(4):418-420. PubMed PMID: 28199155
- Aschner Y, Burnham EL. Adjuvant Therapies for ARDS: Not Ready for Prime Time?. Ann Am Thorac Soc. 2017 Jan;14(1):14-16. PubMed PMID: 28035871
- Aschner Y, Burnham EL. Adjuvant Therapies for ARDS: Not Ready for Prime Time?. Ann Am Thorac Soc. 2017 Jan;14(1):14-16. PubMed PMID: 28035871
- Downey GP, Aschner Y. Taking It Off: New Insights into the Role of Tyrosine Phosphorylation-dependent Pathways in the Pathogenesis of Pulmonary Fibrosis. Am J Respir Crit Care Med. 2017 Feb 15;195(4):418-420. PubMed PMID: 28199155
- Aschner Y, Burnham EL. Adjuvant Therapies for ARDS: Not Ready for Prime Time?. Ann Am Thorac Soc. 2017 Jan;14(1):14-16. PubMed PMID: 28035871
- Downey GP, Aschner Y. Chasing the Lymph: New Clues for the Management of Idiopathic Plastic Bronchitis. Ann Am Thorac Soc. 2016 Oct;13(10):1671-1673. PubMed PMID: 27726438
- Aschner Y, Downey GP. Transforming Growth Factor-ß: Master Regulator of the Respiratory System in Health and Disease. Am J Respir Cell Mol Biol. 2016 May;54(5):647-55. PubMed PMID: 26796672
- Aschner Y, Khalifah AP, Briones N, Yamashita C, Dolgonos L, Young SK, Campbell MN, Riches DW, Redente EF, Janssen WJ, Henson PM, Sap J, Vacaresse N, Kapus A, McCulloch CA, Zemans RL, Downey GP. Protein tyrosine phosphatase a mediates profibrotic signaling in lung fibroblasts through TGF-ß responsiveness. Am J Pathol. 2014 May;184(5):1489-502. PubMed PMID: 24650563
- Yamashita CM, Radisky DC, Aschner Y, Downey GP. The importance of matrix metalloproteinase-3 in respiratory disorders. Expert Rev Respir Med. 2014 Aug;8(4):411-21. PubMed PMID: 24869454
- Aschner Y, Zemans RL, Yamashita CM, Downey GP. Matrix metalloproteinases and protein tyrosine kinases: potential novel targets in acute lung injury and ARDS. Chest. 2014 Oct;146(4):1081-91. PubMed PMID: 25287998
Professional Memberships
- American Thoracic Society, Member
Practice Locations
UCHealth Interstitial Lung Disease Clinic - Anschutz Medical Campus1635 Aurora Ct
Anschutz Outpatient Pavilion, 7th Fl
Aurora, CO 80045
720-848-0748
UCHealth University of Colorado Hospital (UCH)
12605 E. 16th Ave
Aurora, CO 80045
720-848-0000
Hospital Affiliation
- University of Colorado Hospital
Specialty Information
Specialties- Pulmonary Disease, Board Certification
- Critical Care Medicine, Board Certification
- Critical Care
- Lungs and Breathing - Interstitial Lung Disease
- Lungs and Breathing
Clinical Interests
Internal Medicine ( 2010 ) Pulmonary Disease ( 2012 ) Critical Care Medicine ( 2014 )
Care Philosophy
My clinical interests include the diagnosis and management of Interstitial Lung Diseases, as well as care of critically ill patients in the Medical Intensive Care Unit. Interstitial lung diseases are complex group of over 100 rare disorders, including idiopathic pulmonary fibrosis, autoimmune or connective tissue disease-related interstitial lung disease and hypersensitivity pneumonitis being the most common. ILDs are often associated with significant morbidity and mortality. Our group strives to provide comprehensive care for patients with ILD using a multi-disciplinary and multi-dimensional approach to care and research. In the Intensive Care Unit, I diagnose and treat complex critically ill of patients with a wide variety of complex medical conditions, ranging from respiratory failure to septic shock to gastrointestinal bleeding to severe electrolyte and metabolic derangements. In all of my practice settings, I value the opportunity to work with patients and their families. I endeavor to apply rigorous attention to detail, a focus on evidence-based medicine, and a collaborative focus on treatments and interventions.
Internal Medicine ( 2010 ) Pulmonary Disease ( 2012 ) Critical Care Medicine ( 2014 )
Care Philosophy
My clinical interests include the diagnosis and management of Interstitial Lung Diseases, as well as care of critically ill patients in the Medical Intensive Care Unit. Interstitial lung diseases are complex group of over 100 rare disorders, including idiopathic pulmonary fibrosis, autoimmune or connective tissue disease-related interstitial lung disease and hypersensitivity pneumonitis being the most common. ILDs are often associated with significant morbidity and mortality. Our group strives to provide comprehensive care for patients with ILD using a multi-disciplinary and multi-dimensional approach to care and research. In the Intensive Care Unit, I diagnose and treat complex critically ill of patients with a wide variety of complex medical conditions, ranging from respiratory failure to septic shock to gastrointestinal bleeding to severe electrolyte and metabolic derangements. In all of my practice settings, I value the opportunity to work with patients and their families. I endeavor to apply rigorous attention to detail, a focus on evidence-based medicine, and a collaborative focus on treatments and interventions.